Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
Background: The current recommendations for treatment of patients with newly diagnosed acute promyelocytic leukemia (APL) include all-trans-retinoic acid (ATRA) and anthracycline based chemotherapy. Aim: To evaluate the results of the Chilean protocol following the LPA99 regimen of the Spanish PETHE...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2013
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000001 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872013001000001 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720130010000012014-10-10Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, ChileUndurraga,María SoledadPuga,BárbaraCabrera,María ElenaPalma,TamaraRossle,AlbertoVergara,Carmen GloriaRojas,BernarditaAspillaga,Augusto Daunorubicin Leukemia, myeloid, acute Mitoxantrone Tretinoin Background: The current recommendations for treatment of patients with newly diagnosed acute promyelocytic leukemia (APL) include all-trans-retinoic acid (ATRA) and anthracycline based chemotherapy. Aim: To evaluate the results of the Chilean protocol following the LPA99 regimen of the Spanish PETHEMA group, except for the replacement of Idarubicin by Daunorubicin. Patients and Methods: Induction consisted of Daunorubicin 45 mg/m² on days 2, 4, 6 and 8 plus ATRA 45 mg/m² daily until complete remission. Patients in complete remission (CR) received three monthly chemotherapy courses: Daunorubicin 45 mg/m²/d/4days i.v. and ATRA 45 mg/m²/d/15 days p.o. (course no. 1); Mitoxantrone 10 mg/m²/d/5 days i.v. and ATRA 45 mg/m²/d/15 days p.o. (course no. 2); Daunorubicin 60 mg/m²/d/ day 1 i.v. in the low risk group, and 1 and 2 in the intermediate-high risk groups and ATRA 45 mg/m²/d/15 days p.o. (course no. 3). Maintenance therapy consisted of mercaptopurine 90 mg/m²/d p.o., methotrexate 15 mg/m²/wk p.o. and, ATRA intermittently, 45 mg/m²/d p.o. for 15 days every three months. Results: Between January 2000 and December 2005, 56 patients with newly diagnosed APL from 10 centers were enrolled. A total of 46 patients achieved CR (85%), 8 (15%) died of early complications, seven patients relapsed, with a 16% relapse risk at three years. The 5-year Kaplan-Meier estimates of overall survival and relapse-free survival were 64% and 84% respectively. Conclusions: These data indicate that this protocol has a good antileukemic effect but further reduction of early death and relapse, especially in the high risk group is needed.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.141 n.10 20132013-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000001es10.4067/S0034-98872013001000001 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Daunorubicin Leukemia, myeloid, acute Mitoxantrone Tretinoin |
| spellingShingle |
Daunorubicin Leukemia, myeloid, acute Mitoxantrone Tretinoin Undurraga,María Soledad Puga,Bárbara Cabrera,María Elena Palma,Tamara Rossle,Alberto Vergara,Carmen Gloria Rojas,Bernardita Aspillaga,Augusto Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| description |
Background: The current recommendations for treatment of patients with newly diagnosed acute promyelocytic leukemia (APL) include all-trans-retinoic acid (ATRA) and anthracycline based chemotherapy. Aim: To evaluate the results of the Chilean protocol following the LPA99 regimen of the Spanish PETHEMA group, except for the replacement of Idarubicin by Daunorubicin. Patients and Methods: Induction consisted of Daunorubicin 45 mg/m² on days 2, 4, 6 and 8 plus ATRA 45 mg/m² daily until complete remission. Patients in complete remission (CR) received three monthly chemotherapy courses: Daunorubicin 45 mg/m²/d/4days i.v. and ATRA 45 mg/m²/d/15 days p.o. (course no. 1); Mitoxantrone 10 mg/m²/d/5 days i.v. and ATRA 45 mg/m²/d/15 days p.o. (course no. 2); Daunorubicin 60 mg/m²/d/ day 1 i.v. in the low risk group, and 1 and 2 in the intermediate-high risk groups and ATRA 45 mg/m²/d/15 days p.o. (course no. 3). Maintenance therapy consisted of mercaptopurine 90 mg/m²/d p.o., methotrexate 15 mg/m²/wk p.o. and, ATRA intermittently, 45 mg/m²/d p.o. for 15 days every three months. Results: Between January 2000 and December 2005, 56 patients with newly diagnosed APL from 10 centers were enrolled. A total of 46 patients achieved CR (85%), 8 (15%) died of early complications, seven patients relapsed, with a 16% relapse risk at three years. The 5-year Kaplan-Meier estimates of overall survival and relapse-free survival were 64% and 84% respectively. Conclusions: These data indicate that this protocol has a good antileukemic effect but further reduction of early death and relapse, especially in the high risk group is needed. |
| author |
Undurraga,María Soledad Puga,Bárbara Cabrera,María Elena Palma,Tamara Rossle,Alberto Vergara,Carmen Gloria Rojas,Bernardita Aspillaga,Augusto |
| author_facet |
Undurraga,María Soledad Puga,Bárbara Cabrera,María Elena Palma,Tamara Rossle,Alberto Vergara,Carmen Gloria Rojas,Bernardita Aspillaga,Augusto |
| author_sort |
Undurraga,María Soledad |
| title |
Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| title_short |
Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| title_full |
Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| title_fullStr |
Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| title_full_unstemmed |
Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile |
| title_sort |
leucemia promielocítica aguda: resultados del protocolo terapéutico lpa2000, programa nacional de cáncer del adulto (panda), ministerio de salud, chile |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2013 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013001000001 |
| work_keys_str_mv |
AT undurragamariasoledad leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT pugabarbara leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT cabreramariaelena leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT palmatamara leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT rosslealberto leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT vergaracarmengloria leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT rojasbernardita leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile AT aspillagaaugusto leucemiapromielociticaagudaresultadosdelprotocoloterapeuticolpa2000programanacionaldecancerdeladultopandaministeriodesaludchile |
| _version_ |
1718436714952785920 |